Screener
ImmunityBio, Inc. IBRX Impairment of long-lived assets
Impairment of long-lived assets at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:TangibleAssetImpairmentCharges.
The source filing: ImmunityBio, Inc.’s 10-K, filed February 23, 2026.
- Filed
- Feb 23, 2026, 5:24 PM EST
- Fiscal year
- FY2025
- Accession
- 0001326110-26-000030
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Non-cash interest expense related to revenue interest liability | 41,229 | 38,004 | 264 |
| Stock-based compensation expense | 36,809 | 34,432 | 49,163 |
| Depreciation and amortization | 15,525 | 17,554 | 18,512 |
| Loss due to write-off of fixed assets | 14,018 | — | — |
| Change in fair value of derivative liabilities | (6,398) | (13,477) | — |
| Non-cash lease expense related to operating lease right-of-use assets | 3,502 | 3,309 | 3,113 |
| Non-cash lease expense related to operating lease right-of-use assets – related parties | 2,754 | 2,447 | 2,999 |
| Accretion of discounts on marketable debt securities, available-for-sale | (2,745) | (1,489) | (137) |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
FAQ
- What is ImmunityBio, Inc.'s impairment of long-lived assets?
- ImmunityBio, Inc. (IBRX) reported impairment of long-lived assets of $3.5M in Q4 2025.
- What does impairment of long-lived assets mean?
- Specific non-cash charges related to the write-down of physical, long-lived assets such as property, plant, and equipment. This occurs when the expected future cash flows from these assets are insufficient to cover their carrying amount. It highlights the physical capital efficiency of the company's manufacturing or laboratory infrastructure.
Ask your AI about ImmunityBio, Inc.'s impairment of long-lived assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude